



# Award Presentation Ceremony *cum* Award Winners' Lectures of

The First Cheung On Tak International Award for  
Outstanding Contribution to Chinese Medicine

第一屆張安德中醫藥國際貢獻獎

頒獎典禮暨得獎學人講座



香港浸會大學  
HONG KONG BAPTIST UNIVERSITY

School of **中醫藥學院**  
**Chinese Medicine**



張安德中醫藥國際貢獻獎  
CHEUNG ON TAK  
INTERNATIONAL AWARD  
FOR OUTSTANDING CONTRIBUTION  
TO CHINESE MEDICINE

## 張安德中醫藥國際貢獻獎

傳統中醫藥近年發展一日千里，其在人類醫療保健中的作用也日益突顯。香港浸會大學由 2011 年起設立中醫藥國際貢獻獎，目的是推動中醫藥的國際化和現代化，這不僅有益於中國兩岸四地，而且有利於全世界。

承蒙張安德慈善基金慷慨捐獻，香港浸會大學得以設立此獎項，因此特以「張安德中醫藥國際貢獻獎」命名，以此鳴謝。

「張安德中醫藥國際貢獻獎」每兩年頒發一次，每屆獎項最多兩位得獎人，不設等級。獎項頒發予在推動中醫藥國際化或在中醫藥研究領域取得國際性突破成就的科學家和學者。

每屆獎項設獎金港幣 50 萬元。如有兩位得獎人，獎金將平均分配。每位得獎人另獲發獎座及證書。

## 張安德慈善基金

「張安德慈善基金」由張安德先生於 1992 年創辦，其宗旨為促進教育、宗教及醫療事業的發展，扶危解困，造福社群，回饋社會。張先生為一名工業家，曾出任萬寶置業有限公司兼安德企業有限公司顧問。張先生一向熱心公益，並致力履行社會責任，曾在多個社區及工商團體擔任職務，包括潮僑塑膠廠商會會長和主席、香港潮州商會會董、香港仔街坊福利會社會服務中心榮譽會長、南區反吸毒運動主席、香港張氏宗親會會長等。2011 年，張先生獲香港浸會大學頒授榮譽大學院士。



「張安德慈善基金」自成立以來，多年來慷慨捐資，熱心支持本港的教育事業，基金曾先後捐資數間大學，積極推動本港大學的教研發展。



## 第一屆評審委員會

主席



**陳凱先教授**

中國科學院院士  
上海中醫藥大學校長

成員（按英文姓氏排列）



**陳新滋教授**

中國科學院院士  
香港浸會大學校長



**高永文醫生 BBS, JP**

香港防癌會主席  
香港浸會大學中醫藥學院諮詢委員會主席



**梁秉中教授 SBS, OBE, JP**

香港中文大學醫學院  
矯形外科創傷學系創院及終身講座教授  
中醫中藥研究所所長



**劉良教授**

澳門科技大學副校長(研究及拓展)及講座教授  
中藥質量研究國家重點實驗室主任



**蘇國輝教授**

中國科學院院士  
香港大學醫學院解剖學系講座教授兼系主任



**伍焜玉教授**

台灣中央研究院院士  
台灣國家衛生研究院院長



## 第一屆張安德中醫藥國際貢獻獎得獎人




### 陳可冀教授

陳可冀教授為中醫及中西醫結合醫學家、中國科學院資深院士、中國中醫科學院西苑醫院心血管病中心主任，是中國中西醫結合事業的奠基者及開拓者之一。陳教授同時是香港浸會大學及澳門科技大學榮譽博士。

陳教授於 1930 年出生於福建省福州市。1954 年畢業於福建醫學院（現為福建醫科大學）醫療系，同年留校任福建醫學院內科助教及附屬醫院內科住院醫師。1956 年被選調到中國中醫研究院（現為中國中醫科學院），師從名老中醫冉雪峰及著名經方派大師岳美中教授，系統學習中醫和臨證多年。1963 年任中國中醫科學院西苑醫院內科主治醫師，以後續聘為副研究員及研究員。1978 年與著名中醫趙錫武、郭士魁同時被任命為西苑醫院心血管病研究室主任；並被選任為中華醫學會心血管病學會常委。曾任《中華心血管病雜誌》第一至四屆副總編輯。1979 年起擔任世界衛生組織傳統醫學專家諮詢團顧問。1981 年協助季鐘樸教授一起創建中國中西醫結合研究會（現為中國中西醫結合學會）；1996 至 2008 年任中國中西醫結合學會會長。1986 年起任中國科學技術協會第三至五屆常委，現任榮譽委員。1991 年當選為中國科學院學部委員（院士）；1998 至 2004 年任中國科學院生物學部副主任；2004 至 2008 年任中國科學院學部主席團成員。1992 至 2003 年任第七至九屆全國政協委員。2000 年迄今任中華醫學會常務理事及第五、六屆老年醫學學會主任委員。2005 年擔任世界中醫藥學會聯合會心血管病分會會長。現任“Chinese Medical Journal”（《中華醫學雜誌》英文版）、《中華心血管病雜誌》、《中華老年醫學雜誌》及《香港老年醫學雜誌》顧問。

陳教授相繼組建國家中醫藥管理局中醫心血管病重點研究室、重點學科、專病專科中心，成為中醫、中西醫結合心血管病防治研究領域最活躍單位。1981 年所組建的西苑醫院老年醫學研究所，為全國第一所老年醫學研究所，是國家中醫藥管理局重點學科和專病專科中心，現任該中心名譽主任，為中國老年醫學領域的開拓者。創辦《中國中西醫結合雜誌》及“Chinese Journal of Integrative Medicine”期刊，前者引用頻率歷年均列中醫藥及中西醫結合類期刊前茅，後者 2008 年起已獲 SCI-E 列為期刊源。作為主席，陳教授相繼主持召開三屆世界中西醫結合大會，國際學術界反響良好。數十年來先後到美國、英國、法國、日本、瑞士、荷蘭、比利時、韓國、印度、朝鮮、越南、菲律賓、新加坡、馬來西亞、台灣、香港、澳門等國家和地區進行數十次學術交流，促進了國內外中西醫結合學術交流和持續發展，在國際上享負盛譽。






陳教授五十多年來從事心血管病和老年醫學臨床研究，具備豐富的臨床經驗，並開創傳統醫學現代活血化癥學派，使活血化癥治法及相關方藥現成為當代中國中醫藥治療心腦血管病的重要治療方法。對活血化癥相關方藥的作用進行分子水平的研究，從多層次證實其抗血栓素的作用，研發冠心二號複方、川芎嗪、愈心痛、血府逐癥系列方藥取得進展，推動了該領域的研發進展。注重中醫古籍及中醫理論的繼承和研究，主持搶救性整理清代宮廷原始醫藥檔案三萬餘件，出版《清宮醫案研究》等著述六種，完成了前人未能實現的一項中醫藥學術傳承，獲得著名中、西醫專家學者們的高度評價。主編專著二十多部，先後主持中國國家級重大研究課題八項。培養博士、碩士研究生等人才一百二十餘名。1994 年獲首屆「立夫中醫藥學術獎」；2003 年憑「血癥證與活血化癥研究」獲中國國家科技進步一等獎；2007 年獲首屆「世界中醫藥聯合會中醫藥國際貢獻獎」；2007 年被定為中國非物質文化遺產傳統醫藥項目代表性傳承人；2009 年獲「吳階平醫學獎」；2011 年其主編的《清宮醫案集成》獲中國國家新聞出版總署頒發「中國出版政府獎」。

陳教授現任中國中醫科學院首席研究員、中國中醫科學院西苑醫院心血管病中心主任、中國中西醫結合學會名譽會長、中國老年學學會名譽會長、《中國中西醫結合雜誌》及“Chinese Journal of Integrative Medicine”期刊主編、中央保健委員會專家顧問委員會成員、國家中醫藥管理局專家諮詢委員會委員、人事部博士後管委會專家組成員、中國藥典委員會執委、中華醫學會及中國醫師協會常務理事及中國醫師協會中西醫結合醫師分會會長、北京大學醫學部兼任教授、北京大學中醫藥現代研究中心學術委員會主任委員及衰老研究中心學術委員會主任委員、首都醫科大學中西醫結合系學術委員會主任委員、北京市人民政府醫藥專業顧問、衛生部中日友好醫院心血管病中心名譽主任、福建中西醫結合研究院院長、廣東省中醫藥科學院科技委員會主席、世界中醫藥聯合會高級專家顧問委員會副主席、香港浸會大學中醫藥學院、香港大學及香港中文大學名譽教授，以及美國加州大學洛杉磯分校客座教授。

## 第一屆張安德中醫藥國際貢獻獎得獎人



### 鄭永齊教授

鄭永齊教授為美國耶魯大學醫學院藥理學系講座教授、中藥全球化聯盟主席，並兼任中國科學院上海藥物研究所、香港大學醫學院及香港浸會大學中醫藥學院等多所學府的榮譽教授。


鄭教授的藥物研究與開發事業卓爾出色。他取得哲學博士資格後僅七年，便榮獲美國一家主要大學頒授「教授」名銜；四種獲批准並具備臨床重要性的抗病毒藥物 (gancyclovir、lamivudine、clevudine和entricitabine) 皆由他的實驗室發現，如此成就足以使鄭教授舉世知名。自 1989 年起，他榮獲美國耶魯大學醫學院藥理學系 Henry Bronson 講座教授席，1994 年起更成為台灣中央研究院院士，令其成就更隆。鄭教授至今於各大學術期刊內發表了接近四百篇論文作品，包括《自然》(Nature) 和《科學》(Science) 等高影響力醫學期刊。

鄭教授自 1989 年以來，一直是耶魯大學藥理學系的出色一員，在研發治療癌症與過濾性病毒疾病的藥物方面，貢獻重大，主力研究核苷 (nucleosides)、寡核苷酸 (oligonucleotides) 和葉酸類似物 (folate analogs) 等藥物種類，除此之外，亦投身鑽研多種天然產品。

鄭教授是生物化學與分子藥理學的專家權威，對人類健康帶來重大的貢獻。基於藥理和藥物發現均慣用還原論方法，他於過去十年竭誠探討中醫藥作廣泛臨床使用的成果，造就不少醫學突破，成為革新治療的基礎，讓上百萬遭受病症折騰的人士受惠。

鄭教授的研究目標，旨在發掘治癌與治療過濾性病毒疾病的新化學成份，並改善現時採用的化療劑效果。他於 1998 年成立生物化學公司 PhytoCeutica，銳意拓展中醫藥發展，致力研製能取得美國食品及藥物管理局 (FDA) 批准的中醫治癌藥物。

鄭教授透過 PhytoCeutica 公司研發出一項美國食品及藥物管理局認可的技術平台 — Phytomics QC，透過化學與生物指紋圖譜分析，監察中草藥方的一致性。PhytoCeutica 公司更藉此技術把中醫古方「黃芩湯」現代化，使之成為新植物性藥物，名為「PHY906」。新藥物已通過於美國進行第二階段臨床測試。在上述過程中，鄭教授更首創與主要持份者進行正面的互動交流，對象包括美國國立衛生研究院 (NIH)、美國食品及藥物管理局、大學、企業和大眾媒介等。透過嶄新研製 PHY906 藥物的措舉，把中醫藥研究引入主流國際學術社群，相關論文得以



在《科學轉化醫學》(Science Translational Medicine) 等主要醫學期刊見刊，堪稱一大突破。鄭教授在文中提出了明確的論證，指出「黃芩湯」藥方的四種草藥缺一不可，四者合用才可發揮理想的療效，正好印證「君臣佐使」的原則。

2003 年，鄭教授聯同十六位來自主要中醫藥研究機構的代表成立中藥全球化聯盟 (Consortium for Globalization of Chinese Medicine)，並帶領其發展，全球現有超過一百三十所學術成員機構和十所企業成員機構。中藥全球化聯盟是其中一個最大型的國際組織，致力推廣中醫藥文化、教育與研究，全體會員秉承鄭教授與其他創辦人率先定立的「中藥全球化」革新目標邁進。為求達到這個目標，從而更符合全球人士的需要，聯盟定期安排會員會議和合作活動，包括良好實踐中醫藥研究聯盟 (GP-TCM) 等；在中醫藥國際化與現代化的進程上，中藥全球化聯盟可謂一股鮮明的非政府推動力量。

鄭教授致力拓展良好實踐中醫藥研究聯盟於歐洲的會員數目，又大力支持當地研究中醫藥的積極措舉，藉此鼓勵歐洲的中醫藥研究活動，從他出任該會顧問局主席，不斷支持該會各項會議、研究與撥款申請等可見一斑。良好實踐中醫藥研究聯盟是首個第七屆歐盟科研架構計劃 (FP7) 下的聯盟機構，由歐盟撥款支持，遍及二十三個國家。該會矢志透過臨床醫生與科學家的跨學科經驗和專業知識交流，展示實踐中醫藥的最佳做法，並協調中醫藥的安全與功效研究。

除掌理上述會務以外，鄭教授亦應不少從事中醫藥研究與發展的學院和企業邀請，擔當顧問的工作，包括中國科學院 (Chinese Academy of Sciences)、中國醫學科學院 (Chinese Academy of Medical Sciences)、美國國立衛生研究院 (NIH) / 國家補充及另類療法研究中心 (NCCAM)、香港大學及中醫藥研究院 (TCM Research Institute) (澳洲) 等。他對年青研究人員和研究生傾囊相授，對他們的中醫研究項目提供寶貴意見。鄭教授在中醫藥科學研究上取得出色成就，並向國際社會廣泛推廣使用，藉此帶來顯著的社會益處；他在促進國際中醫藥交流與合作上貢獻良多，備受國際同儕肯定；他亦一直締造出色成就，影響宏大，普及國際。




## 節目程序

2012 年 4 月 30 日（星期一）

香港浸會大學林護國際會議中心夏利萊博士演講廳（WLB 103室）

頒獎典禮		下午 3:00 - 3:30
致歡迎辭	香港浸會大學校長 陳新滋教授	
簡介得獎人	第一屆評審委員會主席 陳凱先教授	
頒獎儀式	張安德慈善基金創辦人 張安德先生 及 香港浸會大學校董會暨諮議會主席 王英偉先生SBS, JP 頒授第一屆「張安德中醫藥國際貢獻獎」予 陳可冀教授 及 鄭永齊教授	
得獎人致辭	陳可冀教授 及 鄭永齊教授	
致送紀念品	香港浸會大學校董會暨諮議會主席 王英偉先生SBS, JP 及 香港浸會大學校長 陳新滋教授 致送紀念品予 張安德慈善基金創辦人 張安德先生 及 第一屆評審委員會主席 陳凱先教授	
嘉賓合照	得獎人、評審委員會全體成員 及 眾嘉賓	
茶會及採訪		下午 3:30 - 4:00
得獎學人講座		下午 4:00 - 6:00
陳可冀教授	「傳統與現代共同輝煌」	
鄭永齊教授	「中藥目前情況和未來展望成為世界藥物」	



## 得獎學人講座摘要

### 傳統與現代共同輝煌

#### —— 充分應用現代科學技術推進中西醫學的彙聚

陳可冀教授

(中國中醫科學院西苑醫院內科教授，北京，100091)

現今我國發展中醫藥的政策可歸納為：

1. 中西醫並重
2. 實現中醫藥現代化
3. 促進中西醫結合或彙聚

中國國務院 2003 年發佈的《中華人民共和國中醫藥發展條例》中的第三條進一步指出要：

「推動中醫、西醫兩種醫學體系的有機結合。」

過去半個世紀的臨床實踐表明，中西醫兩種醫學體系的彙聚或結合能夠有效提高中醫藥學的臨床療效和水準。例如：

1. 中醫大師蒲輔周採用加減蒼朮白虎湯治療流行性乙型腦炎的成就；
2. 在防治冠心病冠脈介入術後再狹窄的多中心 RCT 研究表明加用中藥效果較單用西藥標準治療為好；
3. 國際上率先應用砷製劑治療 APL 並證實其在對病患細胞的分化與凋亡機制研究成果；
4. WHO 推薦青蒿素四種複方用於耐藥性病人的抗瘧治療；
5. 特製紅麴製劑(血脂康)用於冠心病二級預防；
6. 類風濕性關節炎的寒熱辨證與治療規律研究成果其他等等。

進一步發展傳統中醫藥，究竟甚麼才是正確的路徑？我以為多元模式的臨床實踐研究，包括中西醫彙聚或結合模式、跨學科創新模式，以及傳統醫學獨立模式，都應該是可取的。不可以不注意國際關注傳統醫學進展的風向標，既要注意傳承，也要提倡有嚴格的思路和設計，不可大而化之。我們的工作目標是以病人為中心，追求對病人的滿意度及貢獻度。

## 得獎學人講座摘要

### 中藥目前情況和未來展望成為世界藥物

鄭永齊教授

(美國耶魯大學醫學院藥理學系講座教授)

全球對於健康需要的模式已由疾病防治轉化至保健的課題，而現今醫藥需要涵蓋的範疇再不止於治療的藥物，而是包含各式預防、功能及輔助性質的藥品。有鑒於癌症、心血管疾病、骨與骨髓功能退化、神經退化、免疫失常及代謝性疾病的致病原因錯綜複雜，目前主流製藥領域採用簡化模式的研發方法不足以針對病源，因此我們需採用多重化學物質藥物，配合系統生物學的方法研製。傳統中藥往往宣稱有治療複雜或多病徵疾病的功效，兼可預防疾病及改善生活質素。這些聲稱的功效，或是源於中藥化學物質的綜合特性，能夠針對人體多重部位發揮效果。傳統中藥朝着全面的模式演進，正是系統生物學的雛形，主流醫藥目前研製的綜合治療藥物以系統生物學為本。若然我們可以印證那些療效，中藥便可望協助醫藥界達至現今未能滿足的臨床要求，並與主流醫藥配對互補，奠下未來醫藥發展的基石。傳統中藥要發展成為現代藥品，備受全球接納及認可，本身必須達至以下的要求：

1. 製劑的程序必須始終如一，那是傳統中藥備受全球接納和認可的一大因素。
2. 必須採用全球認可的準則，建立臨床療效與安全性的佐證。
3. 提供一些相關功效的知識，例如針對不同部位發揮的功效、活躍成分及與現行主流藥物相互產生的療效。

中藥全球化的進程雖然遇上不少荊棘，但近年來醫藥技術與知識發展一日千里，障礙相信可以迎刃而解。在推動中藥發展的前提下，集結不同專科的科學家攜手合作，至關重要。就此，我們於 2003 年於香港成立「中藥全球化聯盟」，致力孕育本地與國際的合作機會，現有一百三十所學術成員機構，以及十所來自業界的企業聯繫成員機構。我將在本文以研製 PHY906 的實驗室經驗為本，一一述說以上的範疇；PHY906 是中藥複方，旨在為接受化學療法的癌症病人提供輔助治療。此外，我亦會談及「中藥全球化聯盟」成立的目的和使命。本研究工作蒙美國國家衛生研究院 (NIH) / 國家癌症研究院 (NCI) 的 #1P01CA154295-01 撥款項目支持。





## Cheung On Tak International Award for Outstanding Contribution to Chinese Medicine

Traditional Chinese medicine has made rapid development over the years. Its therapeutic values for humans are equally gaining prominence. Established by Hong Kong Baptist University (HKBU) in 2011, the Award for Outstanding Contribution to Chinese Medicine aims to promote the internationalization and modernization of Chinese medicine to the benefit of the Greater China as well as the entire world.

The HKBU is indebted to the Cheung On Tak Charity Foundation for its generous donation towards the establishment of the Award. Thereupon, the Award has been named the *Cheung On Tak International Award for Outstanding Contribution to Chinese Medicine* in recognition of the support of the Foundation.

The *Cheung On Tak International Award for Outstanding Contribution to Chinese Medicine* is conferred once every two years. At most two awardees are named in each nomination year for the same prize. The Award is presented to scientists and scholars who have made groundbreaking achievements in advancing the internationalization of Chinese medicine and in the field of Chinese medicine research.

The Award has a monetary prize of HK\$500,000. In the event of double awardees, the prize money shall be divided equally between the awardees. Each awardee shall also receive a trophy and a certificate.

### Cheung On Tak Charity Foundation

The Cheung On Tak Charity Foundation was set up by Mr. Cheung On Tak, a benevolent philanthropist, in 1992. An industrialist renowned for his devotion to education and charity work, Mr. Cheung was the consultant to Man Po Investment Co. Ltd. and On Tak Enterprise Co. Ltd. In addition to his philanthropic work, Mr. Cheung has actively served in various positions in community organizations and industrial and trade associations, including as President and Chairman of The Chiu Chau Plastic Manufacturers Association Company Limited, Director of Hong Kong Chiu Chow Chamber of Commerce, Honorary President of The Aberdeen Kai-fong Welfare Association Social Service Centre, Chairman of Southern District Anti-drug Campaign, President of Hong Kong Cheung Shi Clansmen's Association, etc. In 2011, Mr. Cheung was bestowed with the Honorary University Fellowship by HKBU.



Over the years, the Foundation has made generous donations in support of the teaching and research development of local tertiary institutions.

## Selection Committee of the First Award

### Chairman



**Professor CHEN Kaixian**

*Academician, Chinese Academy of Sciences;*

*President, Shanghai University of Traditional Chinese Medicine*

### Members (in alphabetical order by last name)



**Professor Albert Sun-Chi CHAN**

*Academician, Chinese Academy of Sciences;*

*President and Vice-Chancellor, Hong Kong Baptist University*



**Dr. KO Wing-Man, BBS, JP**

*Chairman, The Hong Kong Anti-Cancer Society;*

*Chairman, Advisory Committee of School of Chinese Medicine,  
Hong Kong Baptist University*



**Professor LEUNG Ping-Chung, SBS, OBE, JP**

*Founding Chairman and Emeritus Professor of Orthopaedics and Traumatology;*

*Director, Institute of Chinese Medicine, The Chinese University of Hong Kong*



**Professor LIU Liang**

*Vice Rector (Research and Development) and Chair Professor,*

*Macau University of Science and Technology;*

*Director, State Key Laboratory of Quality Research in Chinese Medicine*



**Professor SO Kwok-Fai**

*Academician, Chinese Academy of Sciences;*

*Chair Professor and Head, Department of Anatomy, The University of Hong Kong*



**Professor Kenneth Kun-Yu WU**

*Academician, Academia Sinica;*

*President, National Health Research Institutes, Taiwan*



## Award Winners



**Professor CHEN Keji**

Academician of the Chinese Academy of Sciences;  
Director of Cardiovascular Center, Xiyuan Hospital of  
China Academy of Chinese Medical Sciences, China

*Professor Chen Keji is an expert in integrative Chinese and western medicine. He is one of the founders and forerunners of integrative medicine in China.*

Professor Chen was born in 1930 in Fuzhou City of Fujian Province. He graduated in 1954 from the Medical Department of Fujian Medical College (now Fujian Medical University) where he studied and practiced Chinese medicine under Ran Xuefeng, renowned Chinese medicine practitioner; and Yue Meizhong, renowned master of the classic prescription school. In 1963 he joined the Xiyuan Hospital of China Academy of Chinese Medical Sciences as attending doctor of internal medicine, and was later hired as associate researcher. In 1978, he was appointed as head of the research office for cardiovascular diseases at Xiyuan Hospital; also appointed were renowned Chinese medical practitioners Zhao Shiwu and Guo Shihui. In the same year he was appointed as Standing Committee Member of Society of Cardiovascular Diseases of Chinese Medical Association. He was the Associate Editor-in-Chief of the first four editorial boards of Chinese Journal of Cardiology. From 1979 he has been serving as a consultant of the Medical Expert Advisory Group of the WHO.

In 1981, Professor Chen together with Professor Ji Zhongpu founded the Chinese Association of the Integration of Traditional and Western Medicine; between 1996 and 2008 he was the Association's president. From 1986 he has been serving as a standing committee member of the 3<sup>rd</sup> to 5<sup>th</sup> committees of China Association for Science and Technology and he is now an honorary member. In 1991 he was selected as member of the Academic Divisions of the Chinese Academy of Sciences; from 1998 and 2004 he was deputy head of the Biology Department of the Academy; from 2004 to 2008 he was member of the presidium at the Academy. Between 1992 and 2003 he was a member of the 7<sup>th</sup>, 8<sup>th</sup> and 9<sup>th</sup> National Committee of the CPPCC. From 2000 he has been an executive council member of the Chinese Medical Association and chairman of the 5<sup>th</sup> and 6<sup>th</sup> committee of the China Gerontological Society. In 2005 he was president of the Society of Cardiology of the World Federation of Chinese Medicine Societies. He is now adviser to Chinese Medical Journal, Chinese Journal of Cardiology, Chinese Journal of Geriatrics, and Journal of the Hong Kong Geriatric Society.

Professor Chen established the key research laboratory, major disciplines of study, and specialist centre for cardiology under the State Administration of Traditional Chinese Medicine, constituting one of the most active drivers in the realm of integrative approach to prevention and treatment of cardiovascular diseases. In 1981 he founded the Research Centre for Geriatrics at Xiyuan Hospital as the first research unit of its kind in China. The Centre, at which



Professor Chen is now honorary director, is a key disciplinary area and specialist centre under the State Administration of Traditional Chinese Medicine. Professor Chen founded the Chinese and English editions of *Chinese Journal of Integrative Medicine*, the former of which ranked among the most cited journals of its kind while the latter being listed as a SCI-E journal since 2008. Professor Chen has convened as the President three consecutive World Integrative Medicine Congresses, all of which received positive acclaims from the academia. Over the past decades, Professor Chen has engaged in dozens of academic exchange endeavors in the US, the UK, France, Japan, Switzerland, the Netherlands, Belgium, Korea, India, North Korea, Vietnam, the Philippines, Singapore, Malaysia, Taiwan, Hong Kong and Macau, and has promoted the exchange and sustainable development of integrative medicine within China and around the world.

For over 50 years, Professor Chen has been engaged in clinical research on cardiovascular diseases and has accumulated extensive clinical experience. He pioneered the theory of blood circulation activation and stasis removal on the basis of traditional medicine, contributing to the popularization of the method and its relevant formulae as a key treatment for cardio-cerebral vascular diseases. He has conducted research on the effects of blood circulation activating and stasis removing formulae on cellular molecular levels, and has proven on multiple levels the effect of the anticoagulants that the formulae contain. He has made significant contributions to the advancement of the field through many of the classic formulae that he researched on and pioneered. Professor Chen also dedicated his focus to the preservation and research of ancient texts and theories of Chinese medicine. He was responsible for the recovery and collation of some 30,000 primitive medical files from the Qing imperial court, the efforts of which received high praises from renowned Chinese and Western medical specialists and scholars. He has edited some 20 monographs and presided over 8 National Major Fundamental Research Programs. He has supervised some 120 research doctoral and master's degree graduates. In 1994 he was awarded the Lifu Academic Award for Chinese medicine; in 2003 he was awarded the Top Prize of National Science and Technology Progress for his study on blood stasis and blood activation



*Professor Chen Keji (second from right) received the degree of Doctor of Science, honoris causa, from HKBU in its 45<sup>th</sup> Commencement*




and stasis removal. In 2007 he was awarded the World Federation of Chinese Medicine Societies International Award for Outstanding Contribution to Chinese medicine; in the same year he was selected as representative successor of the traditional medicine category of China's non-material cultural heritage. In 2009 he was awarded the Wu Jieping Medicine Science Award; in 2011 he received the Chinese Government Award for Publishing for his study on imperial primitive medical files in Qing Dynasty by the General Administration of Press and Publication.

Professor Chen is now Principal Researcher at the Chinese Academy of Sciences, Director of Cardiovascular Center at Xiyuan Hospital of China Academy of Chinese Medical Sciences, President of Chinese Association of the Integration of Traditional and Western Medicine, Honorary President of China Gerontological Society, Editor-in-Chief of the Chinese and English editions of *Chinese Journal of Integrative Medicine*, member of the Expert Group of Central Health Protection Committee, member of the Expert Group of Post-doctoral Administration Committee, member of the State Committee of Pharmacopoeia, standing committee member of the Chinese Medical Association and Chinese Medical Doctor Association, President of the Society of Integrative Medicine of the Chinese Medical Doctor Association, Adjunct Professor of the Department of Medicine of Peking University, Chairman of the Academic Committees of the Modern Research Center for Traditional Chinese Medicine and Research Center for Aging at Peking University, Chairman of the Academic Committee on Integrative Medicine at Capital Medical University, Expert Medical Advisor for the People's Government of the City of Beijing, Honorary Director of the Centre for Cardiovascular Diseases of the Sino-Japan Friendship Hospital, Dean of Graduate School of the Academy of Integrative Medicine of Fujian, Chairman of Scientific Committee of Guangdong Academy of Chinese Medical Sciences, Honorary Professor of the School of Chinese Medicine of Hong Kong Baptist University, the University of Hong Kong and the Chinese University of Hong Kong, and Visiting Professor at University of California, Los Angeles.



## Award Winners



### Professor Tommy Yung-Chi CHENG

Henry Bronson Professor of Pharmacology, Yale University, USA;  
Chairman, Consortium for Globalization of Chinese Medicine

*Professor Tommy Yung-Chi Cheng has made major contributions to the development of drugs for cancer and viral diseases.*

Professor Cheng has an illustrious and outstanding career in drug research and development. At age 35, he was awarded “Professor” in a leading American university, only 7 years after obtaining his PhD degree. Four approved and clinically important anti-viral drugs (gancyclovir, lamivudine, clevudine, and entricitabine) are discovered by Professor Cheng’s laboratory. Such impeccable accomplishment is coupled with Henry Bronson Professorship of Pharmacology of Yale University School of Medicine since 1989 and the Fellowship of Academia Sinica since 1994. He has authored nearly 400 papers in refereed journals, including high impact journals like *Nature* and *Science*.

Professor Cheng has been a distinguished faculty member in the Department of Pharmacology of Yale University School of Medicine since 1989. During that time, he has made major contributions to the development of drugs for cancer and viral diseases, focusing in particular on nucleosides, oligonucleotides, folate analogs, and a variety of natural products.

A leading expert in biochemical and molecular pharmacology, Professor Cheng has made a profound contribution to human health. Given the success in pharmacology and drug discovery using a conventional reductionist approach, his dedication to exploring the potential of Traditional Chinese Medicine (“TCM”) for widespread clinical use in the last decade has brought many breakthroughs in medicine that have been the basis for groundbreaking therapies to treat diseases that afflict millions.

Professor Cheng’s research goals are to explore new chemical entities for the treatment of cancer and viral diseases and to improve the chemotherapeutic agents currently being used. In 1998 he founded PhytoCeutica Inc., a biotech company committed to the development of TCM and FDA-approved prescription drugs for the treatment of cancer.

With PhytoCeutica, Professor Cheng developed “Phytomics Quality Control” technology (“Phytomics QC”), a technology platform approved by the FDA for monitoring the consistency of herbal formulations through both chemical and biological fingerprinting. PhytoCeutica applied Phytomics QC to the modernization of a TCM formula “Huang Qin Tang” into a new type of botanical drug, PHY906, which has passed phase II clinical trial in the USA. In this process, Professor Cheng pioneered positive interactions with key stakeholders such as National





Institutes of Health, FDA, universities, industries and public media. Bringing TCM research into the mainstream of international academic community through pioneering investigations of PHY906 has led to ground-breaking publications in leading journals such as *Science Translational Medicine*, in which he provided unequivocal evidence that all four herbs in Huang Qin Tang are required to produce optimal therapeutic effects, validating the principle of “Jun-Chen-Zuo-Shi”.

Along with representatives from 16 leading institutions in TCM, Professor Cheng founded the Consortium for the Globalization of Chinese Medicine (“CGCM”) in 2003. Since then, under Professor Cheng’s chairmanship, CGCM has continually grown into a truly international organization with more than 130 institutional members and industrial affiliates. As one of the largest international organizations dedicated to promoting TCM culture, education and research, CGCM is united under the flag of “globalization of Chinese medicine”, an innovative concept first developed by Professor Cheng and his CGCM co-founders. Striving to globalize TCM so that it can better serve the different needs of peoples around the world, CGCM organizes regular meetings and collaborations among its members, including the Good Practice in Traditional Chinese Medicine Research in Post-genomic Era (GP-TCM) consortium, and is an unrivaled non-governmental force in the cause of internationalization and modernization of TCM.

Professor Cheng supports TCM research in Europe, by promoting European membership development of GP-TCM and firmly supporting their initiatives in TCM research, as illustrated by his chairmanship of its Advisory Board and his continuous support to its meetings, research and grant application efforts. Inspired by CGCM and Professor Cheng, GP-TCM, the first ever EU-funded 7<sup>th</sup> Framework Program (FP7) coordination consortium, strives to inform the best practice and harmonize research on the safety and efficacy of TCM through interdisciplinary



Professor Tommy Cheng (third from left) and honorable guests celebrated the success of the 9<sup>th</sup> Meeting of CGCM in the Gala Dinner

exchange of experience and expertise among clinicians and scientists. The consortium provides forums and collaboration platforms on quality control, extraction technology, component analysis, toxicology, pharmacology and regulatory issues of Chinese herbal medicine, as well as on acupuncture studies, with particular emphasis on the application of a functional genomics approach.

In addition to the chairmanship of CGCM, Professor Cheng has also actively served as Consultant or Advisor to leading institutions and industries engaged in research and development, which included Chinese Academy of Medical Sciences, NIH/NCCAM (USA), the University of Hong Kong, TCM Research Institute (Australia), etc. and he always gives valuable comments without reservation to the young researchers and postgraduates for their projects in TCM research area. Professor Cheng has attained outstanding achievement in scientific research on Chinese medicine and promoted its wide application to the international community that yielded significant social benefits; he has also achieved outstanding contribution in advancing international exchanges and collaborations of Chinese medicine and become globally recognized by peers in the international arena for this contribution. He has evidently wielded phenomenal international influence.

Professor Cheng is also an Honorary Professor in Shanghai Institute of Materia Medica of Chinese Academy of Sciences, Faculty of Medicine of the University of Hong Kong, and School of Chinese Medicine of Hong Kong Baptist University.





## Proceedings

Monday, 30 April 2012

Dr. Hari Harilela Lecture Theatre (WLB 103)

Lam Woo International Conference Centre, Hong Kong Baptist University

Award Presentation Ceremony		3:00 - 3:30 p.m.
Welcoming Remarks	Professor Albert S. C. CHAN President and Vice-Chancellor of HKBU	
Introducing Award Winners	Professor CHEN Kaixian Chairman of Selection Committee of the First Award	
Presentation of Award	to	Professor CHEN Keji <i>and</i> Professor Tommy Yung-Chi CHENG
	by	Mr. CHEUNG On Tak Founder of Cheung On Tak Charity Foundation <i>and</i> Mr. Wilfred Y. W. WONG, SBS, JP Chairman of the Council and the Court of HKBU
Award Winners' Speeches	Professor CHEN Keji <i>and</i> Professor Tommy Yung-Chi CHENG	
Presentation of Memento	to	Mr. CHEUNG On Tak Founder of Cheung On Tak Charity Foundation <i>and</i> Professor CHEN Kaixian Chairman of Selection Committee of the First Award
	by	Mr. Wilfred Y. W. WONG, SBS, JP Chairman of the Council and the Court of HKBU <i>and</i> Professor Albert S. C. CHAN President and Vice-Chancellor of HKBU
Group Photograph	Award Winners, Selection Committee Members & Guests	
Refreshment & Press Interview		3:30 - 4:00 p.m.
Award Winners' Lectures		4:00 - 6:00 p.m.
Professor CHEN Keji	"Common Glory of the Traditional and the Contemporary"	
Professor Tommy Yung-Chi CHENG	"Present Status and Future Prospect of Chinese Medicine as Global Medicine"	

## Synopsis of Award Winners' Lectures

### **Common Glory of the Traditional and the Contemporary**

**— Fully utilizing modern science and technology to promote TCM-Western medicine convergence**

**Professor CHEN Keji, MD**

**(Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091)**

The present policy for traditional Chinese medicine (TCM) development is as follows:

1. Equal emphasis on traditional Chinese medicine and western medicine;
2. Realization of modernization of TCM;
3. Promoting TCM-Western medicine integration.

The Regulation 3 of PRC-TCM Regulation also points out that “China would promote the organic integration of traditional and western medical systems”.

The clinical medical practice over half a century shows that the integration or convergence of these two medicines can enhance therapeutic efficacy and standard. Examples include:

1. The achievement of Master Pu Fu-zhou in the treatment of encephalitis B with Modified “Cangzhu Baihu Decoction”;
2. Adding Chinese medicines to routine western medicine treatment in a multi-center trial is proved to be superior to administration of western medicine alone for preventing the restenosis post-PCI;
3. First to propose internationally that the mechanism of action of Arsenic trioxide in treating APL based on the induction of cellular disintegration and differentiation;
4. Four artemisinin-based combination therapies (ACT's) recommended by WHO for the treatment of malaria;
5. Specially produced red yeast rice for secondary prevention of coronary heart disease;
6. The achievement of rheumatoid arthritis therapeutic principle based on Heat/Cold symptom-complex differential diagnosis, etc.

To further study and develop Chinese medicine – which is after all the right way? I think the multiple paradigms of clinical practice including the integrative convergence approach, multi-disciplinary innovative approach, traditional medicine approach etc can be proposed. Of course, we need to pay attention to the international trends for convergence between the traditional and the contemporary. We not only need to emphasize learning and inheriting from the past achievements, but also need to advocate critical thinking and designing for present clinical practice and experimental research, and avoid being careless and negligent. Being patient-centered, our goals for medical care research are to pursue patient satisfaction and a high level of contribution to patient care.





## Synopsis of Award Winners' Lectures

### Present Status and Future Prospect of Chinese Medicine as Global Medicine

**Professor Tommy Yung-Chi CHENG**

(Yale University School of Medicine, New Haven, CT 06520)

The paradigm of health needs in the world has shifted from disease care to health care. Thus, the scope of the medicine needed today is not just therapeutic medicine but also preventative medicine, functional medicine, as well as accessory medicine. Given the complex etiology of cancer, cardiovascular disease, bone and marrow functional degeneration, neuronal degeneration, immune dysfunction and metabolic diseases, the current reductionist approach of mainstream pharmaceutical discovery will not be sufficient. Polychemical medicine with the system biology approach will be needed. TCM often had medical claims for the treatment of complicated diseases or multiple symptoms as well as disease prevention and improvement in the quality of life. Those multiple claims for giving Chinese medicine may be due to the complexity of chemicals which could target on multiple sites. The evolvement of TCM took a holistic approach is an early form of “system biology” based “integrative medicine” which is currently pursued by mainstream medicine. Thus, if those claims are proven, it will help to meet current unmet clinical needs. It could also serve in complementation with mainstream medicine as a cornerstone to develop future medicine. In order to be accepted globally, it has to fulfill the requirements for developing modern medicine:

1. Preparation needs to be consistent. This is a major issue for TCM to be accepted globally.
2. Evidence for clinical efficacy and their safety of TCM are needed to be established using globally accepted criteria.
3. Certain knowledge of its action such as the sites of action, active ingredients and the interaction with currently used mainstream medicine.

Those hurdles of developing TCM as a global medicine could be addressed given the technology and knowledge advancement in recent years. Collaboration among scientists with different areas of expertise is crucial in advancing TCM. A “Consortium for the Globalization of Chinese Medicine” (CGCM) was formed in Hong Kong in 2003 and currently has 130 Academic Institution Members and ten affiliated industrial Members. It could serve as the platform to cultivate intra- and international collaborations. In this presentation, I will address each of those areas based on my laboratory experience in developing PHY906, a TCM formula as adjuvant therapy for cancer patients undergoing chemotherapy. I will also introduce the mission and purpose of CGCM. This work is supported by grant #1PO1CA154295-01 from NIH/NCI, USA.

香港浸會大學中醫藥學院

School of Chinese Medicine, Hong Kong Baptist University

地址 Address : 香港九龍塘浸會大學道七號賽馬會中醫藥學院大樓  
Jockey Club School of Chinese Medicine Building,  
7 Baptist University Road, Kowloon Tong, Kowloon, Hong Kong

電話 Tel : (852) 3411 5387

傳真 Fax : (852) 3411 2902

電郵 Email : [scm@hkbu.edu.hk](mailto:scm@hkbu.edu.hk)

網址 Website : <http://scm.hkbu.edu.hk>